Lack Of Globally Accepted Definition of “Counterfeit Drug” Hurts U.S. FDA, Department Of Commerce Drive To Tackle Problem
This article was originally published in PharmAsia News
Executive Summary
Efforts by global stakeholders - including national governments, nongovernmental organizations, and drug companies - to curtail counterfeit drug production are hampered by the lack of an agreed-upon definition for "counterfeit.